Products for Research Use Only
RegisterLogin

Saracatinib

CAT: 0804-HY-10234-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10234-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases[1].
CAS Number
379231-04-6
Product Name Alternative
AZD0530
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; Src
Type
Reference compound
Related Pathways
Autophagy; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Saracatinib.html
Purity
99.28
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
ClC1=CC=C2C(OCO2)=C1NC3=C4C(OC5CCOCC5)=CC(OCCN6CCN(C)CC6)=CC4=NC=N3
Molecular Formula
C27H32ClN5O5
Molecular Weight
542.03
Precautions
H302, H315, H319, H335
References & Citations
[1]Green TP, et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol Oncol, 2009, 3 (3), 248-261.|[2]Fuse MA, et al. Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol Cancer Ther. Mol Cancer Ther. 2017 Nov;16 (11) :2387-2398.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3

Alternative Products

CatalogName
020838-01Saracatinib
A2133-100Saracatinib (AZD0530)
A10108-100Saracatinib 100mg
TKB42872Saracatinib difumarate

Popular Products